Focus on healthcare innovators and established care models

Our capabilities and global platform are unique to the mid-market. With significant experience and deep relationships with corporates and financial sponsors investing in multiple sub-sectors, we are able to deliver tailored and focused advice to clients.

Sub–sectors

Our global Healthcare team has extensive experience across a broad range of healthcare sub-sectors, with a track record in delivering results for clients, anywhere in the world.

  • Care & services
  • Healthcare IT & supply chain
  • Medtech & life sciences
  • Pharma
Japan
Industrials
Advised
  • Sumitomo Bakelite Co., Ltd.
on its acquisition of remaining 76.95% stake in
  • Kawasumi Laboratories, Inc.
Value: ¥27bn
United States
Education
Advised
  • TrueLearn
on a majority investment from
  • LLR Partners
Japan
Healthcare
Advised
  • Matsumoto kiyoshi Holdings
on the acquisition of a minority stake in
  • Cocokara Fine Inc.
Value: $353m
Japan
Healthcare
Advised
  • Nippon Sangyo Suishin Kiko
on the sale of
  • Vati Co., Ltd
Ireland
Infrastructure
Advised
  • iCon Infrastructure
on the acquisition financing for
  • Nua Healthcare
France
Germany
Italy
Healthcare
Advised
  • Sanofi
on the sale of
  • OTC products BoxaGrippal® and Heumann Tee to Angelini Pharma
Value: €47m
France
Healthcare
Advised
  • Almaviva Santé & Antin IP
on the acquisition of
  • Turin & Monceau Private Hospitals
India
Healthcare
Advised
  • InformDS Technologies (Doxper)
on a growth equity raise from
  • Alkemi Venture Partners, GrowX Ventures and others
India
Switzerland
United States
South Korea
Consumer, Leisure & Retail
Advised
  • 1mg Technologies
on a Series D investment of $70m from
  • Corisol Holdings, IFC and others
Poland
Healthcare
Advised
  • Resource Partners
on the sale of
  • Mavit to Grupa Lux Med
Vietnam
Japan
Healthcare
Advised
  • Taisho Pharmaceutical Holdings
on the acquisition of a minority stake in
  • DHG Pharmaceutical
Value: ¥16bn
Japan
Healthcare
Advised
  • Sumitomo Bakelite
on the acquisition of shares in
  • Kawasumi Laboratories
South Korea
Healthcare
Advised
  • Neusoft Medical Systems
on the acquisition of
  • Humanscan
United States
Japan
Healthcare
Advised
  • Chiral Technologies
on the acquisition of
  • Arbor Biosciences
Germany
Healthcare
Advised
  • Tempus Capital and Deutsche Radiologie Holding
on the issuance of an add-on acquisition financing
Japan
France
United States
Healthcare
Advised
  • Taisho Pharmaceuticals
on the acquisition of
  • UPSA from Bristol-Myers Squibb Company
Value: ¥1.6bn

For important information regarding transactions, please see our disclaimer.

I would like to thank DC Advisory for a job well done! Their structured advice throughout the process, along with a deep strategic insight into the potential buyers, was critical in bringing this deal to a successful close.

Xavier Houy, Corporate Director M&A, Head of Divestments, Sanofi

For important information regarding testimonials, please see our disclaimer.

UK Reportage 0125

Solutions

Delivering tailored and impactful solutions, DC Advisory leverages product experts across multiple markets – combining M&A, debt, coverage and specific capital raising expertise.

Select solution
Back to top

Your briefcase is empty

You can save PDFs to download our deal announcements and team profiles.

Briefcase
Category
Information
Actions
    The item(s) added to the briefcase may be lost if this browser is closed.